Satellos Bioscience, Inc. (MSLE) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$9.72

From 52W high−28.36%

Volume19314.00

Market cap$197.74M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$9.72

From 52W high

−28.36%

Volume

19314.00

Market cap

$197.74M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.8x

P/E (TTM)

—

RSI (14)

51.3

MomentumView details →

1D Return

−3.72%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−57.34%

ROA (TTM)

−52.23%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−23.08%

FCF YoY

−42.34%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−79.01%

MomentumView details →

1D Return

−3.72%

YTD Return

—

1Y Return

—

RSI (14)

51.3

vs 50D SMA

+0.41%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

11.22x

Quick Ratio

11.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.56

EPS Surprise

−9.73%

Beats (12Q)

0/12

Next Q EPS Est

−$0.59

Avg Surprise (4Q)

−13.84%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−34.31M

Op. CF (TTM)

−28.67M

Next earningsNov 13, 2026 →

Latest newsMore news →

Satellos Bioscience Inc. reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy.74d ago

The U.S. Food and Drug Administration granted Fast Track designation to Satellos Bioscience's drug candidate SAT-3247 for Duchenne muscular dystrophy.83d ago

Similar companies

Tycoon Group Holdings Limited03390.HK High Tide Inc.HITI Kingworld Medicines Group Limited01110.HK LifeMD, Inc.LFMD Vicore Pharma Holding ABVCRE Clinuvel Pharmaceuticals Ltd.CUVL Find similar companies →

Latest newsMore news →

Satellos Bioscience Inc. reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy.74d ago The U.S. Food and Drug Administration granted Fast Track designation to Satellos Bioscience's drug candidate SAT-3247 for Duchenne muscular dystrophy.83d ago